Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow

Pharmacogenomics Journal

Volumn 3, Issue 4, 2003, Pages 227-234

  Pereira, A ^a,b   McLaren, A ^a   Bell, W R ^a   Copolov, D ^a   Dean, B ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Agranulocytosis; Bone marrow stromal cells; Clozapine; mRNA; Neurotransmitter receptors; Neutrophils

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; NEUROTRANSMITTER RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR;

AGRANULOCYTOSIS; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING SITE; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC CODE; GRANULOPOIESIS; HEMATOPOIESIS; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NEUTROPHIL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECEPTOR BINDING; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

BASE SEQUENCE; BINDING SITES; BONE MARROW CELLS; CELLS, CULTURED; CLOZAPINE; DNA, COMPLEMENTARY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MOLECULAR SEQUENCE DATA; NEUTROPHILS; POLYMERASE CHAIN REACTION; RECEPTORS, NEUROTRANSMITTER; RNA, MESSENGER;

EID: 0141701977     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500179     Document Type: Article

References (66)

1. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995; 3: 64-75.
2. Ashby Jr C, Wang R. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 1996; 24: 349-394.
3. Kinon B, Lieberman J. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996; 124: 2-34.
4. Safferman AZ, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17: 247-261.
5. Young CR, Bowers Jr MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24: 381-390.
6. Rechlin T, Claus D, Weis M. Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine. Biol Psychiatry 1994; 35: 888-892.
7. Hayes G, Gibler B. Clozapine-induced constipation (letter). Am J Psychiatry 1995; 152: 298.
8. Umbritcht DSG, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55: 157-160.
9. Copolov D, Bell W, Benson W, Keks N, Strazzeri D, Johnson G. Clozapine treatment in Australia: a review of haematological monitoring. Med J Aust 1998; 168: 495-497.
10. Lieberman J, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992; 63: 51-70.
11. Gerson SL. G-CSF and the management of clozapine-incluced agranulocytosis. J Clin Psychiatry 1994; 55: 139-142.
12. Pirmohamed M, Park K. Mechanism of clozapine-incluced agranulocytosis: current status of research and implications for drug development. CNS Drugs 1997; 2: 139-158.
13. Liu ZC, Uetrecht JP. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 1995; 275: 1476-1483.
14. Gardner I, Leeder JS, Chin T, Zahid N, Uetrecht JP. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol Pharmacol 1998; 53: 999-1008.
15. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000; 58: 207-216.
16. Guest I, Uetrecht J. Drugs that induce neutropenia/agranulocytosis may target specific components of the stromal cell extracellular matrix. Med Hypotheses 1999; 53: 145-151.
17. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994; 86: 555-561.
18. Uetrecht JP. The role of leukocyte-generated metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992; 24: 299-366.
19. Yamazaki K, Allen T. Ultrastructural morphometric study of efferent nerve terminals on murine bone marrow stromal cells, and the recognition of a novel anatomical unit: the 'neuro-reticular complex'. Am J Anat 1990; 187: 261-276.
20. Broome C, Whetton A, Miyan J. Neuropeptide control of bone marrow neutrophil production is mediated by both direct and indirect effects on CFU-GM. Br J Haematol 2000; 108: 140-150.
21. Amenta F, Bronzetti E, Felici L, Ricci A, Tayebati S. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J Auton Pharmacol 1999; 19: 151-159.
22. Ricci A, Bronzetti E, Mulatero P, Schena M, Veglio F, Amenta F. Dopamine D3 receptor in peripheral mononuclear cells of essential hypertensives. Hypertension 1997; 30: 1566-1571.
23. Ricci A, Bronzetti E, Felici L, Greco S, Amenta F. Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with [3H]7-OH-DPAT: a combined radioligand binding assay and immunochemical study. J Neuroimmunol 1998; 92: 191-195.
24. Ricci A, Bronzetti E, Felici L, Tayebati S, Amenta F. Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci Lett 1997; 229: 130-134.
25. Ricci A, Amenta F. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study. J Neuroimmunol 1994; 53: 1-7.
26. Bronzetti E, Adani O, Amenta F, Felici L, Mannino F, Ricci A. Muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes. Neurosci Lett 1996; 208: 211-215.
27. Tayebati S, Codini M, Gallai V, Mannino F, Parnetti L, Ricci A et al. Radioligand binding assay of M1-M5 muscarinic cholinergic receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 1999; 99: 224-229.
28. Ricci A, Bronzetti E, Conterno A, Greco S, Mulatero P, Schena M et al. Alpha1-adrenergic receptor subtypes in human peripheral blood lymphocytes. Hypertension 1999; 33: 708-712.
29. Titinchi S, Clark B. Alpha 2-adrenoceptors in human lymphocytes: direct characterisation by [3H]yohimbine binding. Biochem Biophys Res Commun 1984; 121: 1-7.
30. Goin J, Sterin-Borda L, Borda E, Finiasz M, Fernandez J, de Bracco M. Active alpha 2 and beta adrenoceptors in lymphocytes from patients with chronic lymphocytic leukemia. Int J Cancer 1991; 49: 178-181.
31. Vile J, Strange P. D2-like dopamine receptors are not detectable on human peripheral blood lymphocytes. Biol Psychiatry 1996; 40: 881-885.
32. Bondy B, de Jonge S, Pander S, Primbs J, Ackenheil M. Identification of dopamine D4 receptor mRNA in circulating human lymphocytes using nested polymerase chain reaction. J Neuroimmunol 1996; 71: 139-144.
33. Bany U, Ryzewski J, Maslinski W. Relative amounts of mRNA encoding four subtypes of muscarinic receptors (m2-m5) in human peripheral blood mononuclear cells. J Neuroimmunol 1999; 97: 191-195.
34. Ricci A, Bronzetti E, Mignini F, Tayebati 5, Zaccheo D, Amenta F. Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 1999; 96: 234-240.
35. Guest I, Uetrecht J. Drugs that induce neutropenia/agranulocytosis may target specific components of the stromal cell extracellular matrix. Med Hypotheses 1999; 53: 145-151.
36. Sato K, Fujii T, Watanabe Y, Yamada S, Ando T, Kazuko F et al. Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci Lett 1999; 266: 17-20.
37. Nagai Y, Ueno S, Saeki Y, Soga F, Yanagihara T. Expression of the D3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem Biophys Res Commun 1993; 194: 368-374.
38. Sookhai S, Wang J, McCourt M, O'Connell D, Redmond H. Dopamine induces neutrophil apoptosis through a dopamine D-1 receptor-independent mechanism. Surgery 1999; 126: 314-322.
39. Sanyal S, Van Tol. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. J Psychiatr Res 1997; 31: 219-232.
40. Shaikh S, Collier D, Sham P, Pilowsky L, Sharma T, Lin L et al. Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am J Med Genet 1995; 60: 541-545.
41. Rietschel M, Naber D, Oberlander H, Holzbach R, Fimmers R, Eggermann K et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996; 15: 491-496.
42. Egorova A, Uspenskaia I, Kruglik O, Nefedova V, Ivanov V, Nefedov V. Disorder of the serotoninergic regulation of bone marrow cell proliferation under the action of a xenobiotic inducer of oxidative stress. Eksp Klin Farmakol 1998; 61: 34-37.
43. Sternberg E, Trial J, Parker C. Effect of serotonin on murine macrophages: suppression of la expression by serotonin and its reversal by 5-HT2 serotonergic receptor antagonists. J Immunol 1986; 137: 276-282.
44. Hauser S, Waldron J, Upuda K, Lipschitz D. Morphological characterization of stromal cell types in hematopoietically active long-term murine bone marrow cultures. J Histochem Cytochem 1995; 43: 371-379.
45. Maestroni G, Conti A. Modulation of hematopoiesis via alpha 1-adrenergic receptors on bone marrow cells. Exp Hematol 1994; 22: 313-320.
46. Corbel S, Schneider E, Lemoine F, Dy M. Murine hematopoietic progenitors are capable of both histamine synthesis and uptake. Blood 1995; 86: 531-539.
47. Tan M, Pan Z, Wang Q, Xu Y. Effects of different subtypes of histamine receptors on proliferation and differentiation of murine colony forming unit granulocyte-macrophage and colony forming unit megakaryocyte. Chin Med J (Engl) 1998; 111: 132-135.
48. Jenssen H, Eckert R, Mix E, Schulz U, Schnitzler S. Histamine-receptor bearing lymphocytes. II. The use of flow cytofluorometric analysis of histamine-receptors on mouse lymphocytes of different organs. Acta Biol Med Ger 1982; 41: 625-633.
49. Ching T, Koelemij J, Bast A. The effect of histamine on the oxidative burst of HL60 cells before and after exposure to reactive oxygen species. Inflamm Res 1995; 44: 99-104.
50. Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J et al. Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol 2001; 59: 420-426.
51. Hellstrom-Lindahl E, Nordberg A. Muscarinic receptor subtypes in subpopulations of human blood mononuclear cells as analyzed by RT-PCR technique. J Neuroimmunol 1996; 68: 139-144.
52. Fujino H, Kitamura Y, Yada T, Uehara T, Nomura Y. Stimulatory roles of muscarinic acetylcholine receptors on T cell antigen receptor/CD3 complex-mediated interleukin-2 production in human peripheral blood lymphocytes. Mol Pharmacol 1997; 51: 1007-1014.
53. Kawashima K, Fujii T, Watanabe Y, Misawa H. Acetylcholine synthesis and muscarinic receptor subtype mRNA expression in T-lymphocytes. Life Sci 1998; 62: 1701-1705.
54. Naumann R, Felber W, Heilemann H, Reuster T. Olanzapine-induced agranulocytosis (letter). Lancet 1999; 354: 566-567.
55. Ruhe HG, Becker HE, Jessurun P, Marees CH, Heeringa M, Vermeulen HDB. Agranulocytosis and granulocytopenia associated with quetiapine. Acta Psychiatr Scand 2001; 104: 311-313.
56. Gardner I, Zahid N, MacCrimmon D, Uetrecht JP. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol 1998; 53: 991-998.
57. Gartner S, Kaplan H. Long-term culture of human bone marrow cells. Proc Natl Acad Sci U S A 1980; 77: 4756-4759.
58. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
59. Giros B, Sokoloff P, Martres M, Riou J, Emorine L, Schwartz J. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 1989; 342: 923-926.
60. Griffon N, Crocq M, Pilon C, Martres M, Mayerova A, Uyanik G et al. Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet 1996; 67: 63-70.
61. Xie E, Zhu L, Zhao L, Chang L. The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant. Genomics 1996; 35: 551-561.
62. 3 receptor cDNAs. Ann NY Acad Sci 1998; 15: 234-235.
63. 7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization. J Neurochem 1997; 68: 1372-1381.
64. Cook Jr E, Fletcher K, Wainwright M, Marks N, Yan S, Leventhal B. Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor. J Neurochem 1994; 63: 465-469.
65. Kohen R, Metcalf M, Khan N, Druck T, Huebner K, Lachowicz J et al. Cloning, characterization and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996; 66: 47-56.
66. Chang D, Chang T, Yamanishi S, Salazar F, Kosaka A, Khare R et al. Molecular cloning, genomic characterization and expression of novel human alpha1 A-adrenoceptor isoforms. FEBS Lett 1998; 422: 279-283.